Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-05

Clinical Trial Update: A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of MR13A9 in hemodialysis patients with uremic pruritus has completed, and results were posted on December 5, 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MR13A9

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Uremic Pruritus | Phase 2 | Status: COMPLETED | Results posted: 2025-12-05